プロモーションスケジュール Context Therapeutics Inc.
詳細なスケジュール
簡易グラフ
会社について
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
EBITDA |
-0.0054 |
Число акций ао |
0.01597 млрд |
P/BV |
0.9592 |
EV/EBITDA |
-4.02 |
Цена ао |
1.27 |
ISIN |
US21077P1084 |
Сайт |
https://www.contexttherapeutics.com
|
Валюта |
usd |
IPO date |
2021-10-20 |
Sector |
Health Care |
Industry |
Pharmaceuticals |
Валюта отчета |
usd |
1日あたりの価格変動: |
-0.5051% (1.98) |
週ごとの価格変動: |
+5.91% (1.86) |
月ごとの料金変更: |
-13.6% (2.28) |
3ヶ月間の価格変動: |
+7.07% (1.84) |
半年間の価格変動: |
+50.38% (1.31) |
年間の価格変動: |
+45.93% (1.35) |
年初からの価格変動: |
+95.05% (1.01) |
|
過小評価
名前 |
意味 |
学年 |
P/S |
0 |
0 |
P/BV |
1.55 |
8 |
P/E |
0 |
0 |
EV/EBITDA |
-0.1593 |
0 |
合計: |
|
3.5 |
|
効率
名前 |
意味 |
学年 |
ROA, % |
-149.19 |
0 |
ROE, % |
-201.87 |
0 |
合計: |
|
0 |
|
|
配当金
名前 |
意味 |
学年 |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
合計: |
|
0 |
|
義務
名前 |
意味 |
学年 |
Debt/EBITDA |
-0.0022 |
10 |
合計: |
|
9.8 |
|
成長の衝動
名前 |
意味 |
学年 |
収益性 Revenue, % |
0 |
0 |
収益性 Ebitda, % |
364.08 |
10 |
収益性 EPS, % |
104.74 |
10 |
合計: |
|
8 |
|
スーパーバイザー |
役職 |
支払い |
生年 |
Mr. Martin A. Lehr |
Co-Founder, President, CEO & Director |
674.08k |
1984 (40 年) |
Ms. Jennifer Minai-Azary |
CFO & Treasurer |
504.14k |
1978 (46 年) |
Mr. Alex C. Levit Esq. |
Chief Legal Officer & Corporate Secretary |
483.83k |
1979 (45 年) |
Mr. Christopher Beck M.B.A. |
Senior Vice President of Operations |
N/A |
|
Dr. Claudio Dansky Ullmann M.D. |
Chief Medical Officer |
|
|